District Court, S.D. New York August 7, 2015, No. 15 Civ. 3588(PAE) (Amarin Pharma, Inc. v. United States Food & Drug Administration)

Also known as

United States · · · 07-08-2015

OPINION & ORDER

PAUL A. ENGELMAYER, District Judge:

In United States v. Caronia, 703 F.3d 149 (2d Cir.2012), the Court of Appeals for the Second Circuit vacated a pharmaceutical sales representative’s conviction for conspiring to introduce a misbranded drug into interstate commerce, in violation of 21 U.S.C. §§ 331(a) and 333(a)(1). The conviction was based" on Caronia’s having promoted a drug for “off-label use,” that is, a use other than the one approved by the U.S. Food and Drug Administration (the “FDA”). Caronia’s conduct to promote the off-label use, however, had consisted solely of truthful and non-misleading speech. The Second Circuit held that, to avoid infringing the First Amendment, the misbranding provisions of the Federal Food, Drug and Cosmetic Act (the “FDCA”) must be construed “as not prohibiting and criminalizing the truthful off-label promotion of FDA-approved prescription drugs” where the off-label use itself is lawful. 703 F.3d at 168.

This case grows out of the decision in Caronia and involves the same misbrand-ing provisions. Plaintiff Amarin Pharma, Inc. (“Amarin”) manufactures a triglyceride-lowering drug, Vascepa. The FDA has approved Vascepa for one use, but doctors have widely, and lawfully, prescribed it for another. Amarin wishes to make truthful statements to doctors relating to Vascepa’s off-label use. The specific statements Amarin seeks to make are derived largely from an FDA-approved study of Vascepa’s off-label use, and from writings by the FDA itself on that subject. Amarin therefore contends, and the FDA largely but not wholly concedes, that the statements Amarin seeks to make are truthful and non-misleading. However, the FDA, recognizing that Amarin’s purpose in making these statements would be to.promote an unapproved use of Vascepa, has threatened to bring misbranding charges against Amarin (and, presumably, its émployees) if it does so.

Read the full text

This document is published by courtlistener.com.

Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.